Is REGN a good stock to buy? We came across a bullish thesis on Regeneron Pharmaceuticals, Inc. on Ocular Capital’s Substack. In this article, we will summarize the bulls’ thesis on REGN. Regeneron Pharmaceuticals, Inc.'s share was trading at $774.66 as of March 11th. REGN’s trailing and forward P/E were 18.68 and 18.05, respectively according to Yahoo Finance.

Nestor Rizhniak/Shutterstock.com

Regeneron Pharmaceuticals, Inc. (REGN) stands out as a powerful innovation engine within the biopharmaceutical industry, driven by strong foundational science and a proven ability to commercialize breakthrough therapies. At the center of its growth story is Dupixent, a blockbuster drug that has rapidly become one of the most successful treatments in modern medicine. Originally approved for atopic dermatitis, Dupixent has expanded into additional indications such as asthma and other inflammatory diseases, demonstrating exceptional efficacy and a widening patient base.

The drug is widely expected to become one of the best-selling pharmaceuticals of all time, generating significant and recurring revenue for the company. This powerful cash flow allows Regeneron to reinvest heavily into research and development, creating a self-sustaining cycle of innovation. Rather than relying on a single product, Regeneron Pharmaceuticals, Inc. has built a broad and promising pipeline spanning oncology, cardiovascular medicine, and rare diseases. The company’s proprietary platforms and scientific expertise enable it to continuously identify and develop new therapies, reinforcing its long-term competitive positioning in the biotech sector.

This strategy transforms the success of Dupixent into a funding engine for future breakthroughs, allowing the company to pursue multiple high-value opportunities simultaneously. As a result, Regeneron Pharmaceuticals, Inc. is not merely benefiting from a temporary blockbuster drug but has established a durable innovation platform capable of delivering sustained growth. With a highly profitable flagship therapy and a deep pipeline supported by strong scientific infrastructure, the company is positioned to remain a major force in the global biopharmaceutical market for years to come.

Previously, we covered a bullish thesis on CRISPR Therapeutics AG (CRSP) by MADD-Scientis in March 2025, which highlighted the commercial potential of Casgevy for sickle cell disease, improving insurance reimbursement, and a promising gene-editing pipeline. CRSP’s stock price has appreciated by approximately 21.86% since our coverage. Ocular Capital shares a similar view but emphasizes on Regeneron Pharmaceuticals, Inc. (REGN)’s Dupixent-driven growth and its self-funding innovation pipeline.

Regeneron Pharmaceuticals, Inc. is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 75 hedge fund portfolios held REGN at the end of the fourth quarter which was 78 in the previous quarter. While we acknowledge the risk and potential of REGN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than REGN and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW

Disclosure: None.